Capital International Inc. CA Grows Stock Position in Amgen Inc. $AMGN

Capital International Inc. CA grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 22.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 386,784 shares of the medical research company’s stock after acquiring an additional 71,908 shares during the quarter. Amgen comprises approximately 0.9% of Capital International Inc. CA’s investment portfolio, making the stock its 29th largest holding. Capital International Inc. CA’s holdings in Amgen were worth $109,150,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AMGN. Capital International Investors lifted its stake in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares during the period. Capital Group Investment Management PTE. LTD. boosted its position in Amgen by 93.4% in the third quarter. Capital Group Investment Management PTE. LTD. now owns 11,732 shares of the medical research company’s stock valued at $3,311,000 after buying an additional 5,666 shares during the last quarter. Bank of Montreal Can increased its holdings in Amgen by 5.3% in the 3rd quarter. Bank of Montreal Can now owns 1,063,079 shares of the medical research company’s stock worth $300,001,000 after buying an additional 53,566 shares during the period. Legal & General Group Plc lifted its stake in Amgen by 5.0% during the 3rd quarter. Legal & General Group Plc now owns 3,716,957 shares of the medical research company’s stock valued at $1,048,925,000 after acquiring an additional 177,325 shares during the period. Finally, Pinkerton Wealth LLC increased its stake in shares of Amgen by 11.5% in the third quarter. Pinkerton Wealth LLC now owns 17,976 shares of the medical research company’s stock worth $5,073,000 after acquiring an additional 1,850 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Morgan Stanley raised their price objective on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. DZ Bank boosted their price objective on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Finally, Piper Sandler lifted their target price on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $354.17.

Amgen Stock Up 2.0%

NASDAQ:AMGN opened at $376.97 on Tuesday. The stock has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s fifty day moving average is $354.21 and its two-hundred day moving average is $323.38. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.